Psychopharmacology of the anxiety disorders.
Although anxiety is a familiar part of all our lives, pathologic anxiety states that lead to occupational and social dysfunction require medical treatment. Currently, the anxiety disorders are divided into nonphobic and phobic disorders. However, recent studies suggest that the disorders should be divided into three symptom groups: (1) generalized anxiety, (2) episodes with severe panic anxiety (panic attacks) plus generalized anxiety or even phobic avoidance, and (3) phobic anxiety and avoidance (alone, without panic attacks). This grouping is highly predictive of response to antianxiety medications. The generalized anxiety group responds well to psychosocial/psychotherapy treatments and to the antianxiety BZs. Many people with nonpanic, nonphobic (situational or generalized) anxiety only require simple psychotherapy or other nonpharmacologic methods to manage their anxiety. However, if the anxious patient is becoming dysfunctional or symptomatology is severe or persistent enough to warrant the use of medication, BZs are certainly the drugs of choice. Despite persistent public or media opinion that they are over-utilized or over-prescribed, most objective data suggest this is not the case. Most individuals for whom they are prescribed need them, use them in proper doses, and discontinue them when the indication passes. Most of the reported abuse occurs in the approximately 8 to 12 per cent who abuse other drugs, most notably alcohol. As anxiety is usually transient, BZs should be prescribed for limited periods (1 to 4 weeks) and then discontinued. This practice allows the physician to properly monitor the amount utilized and to evaluate need for continued BZs. The principal differences among the available BZs are their elimination half-lives, with some greater than 24 hours and others in the 8 to 12 hour range. Side effects are mostly mild (sedation, clumsiness) and drug-drug interactions are uncommon. Until recently, most patients suffering from disorders with panic attacks with or without phobias were either untreated or treated with long, but largely unsuccessful, treatments. Blockade of panic attacks with TCAs, MAOIs and alprazolam has dramatically improved our ability to treat these disorders, with 60 to 95 per cent of patients reporting marked alleviation of symptoms. Adequate amounts of medication and length of treatment period are the keys to successful treatment. This is a period of much productive interest and research in the anxiety disorders. Continued rapid progress in the understanding of the biologic substrates of these conditions and the development of new treatments promise much in this area of medicine in the near future.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000379:Agoraphobia / Q000175:diagnosis; D000525:Alprazolam; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003887:Desensitization, Psychologic; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis; D010200:Panic / Q000187:drug effects; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy; D012306:Risk; D012894:Sleep Stages; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D019966:Substance-Related Disorders / Q000523:psychology
D000319:Adrenergic beta-Antagonists; D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D001569:Benzodiazepines; D000525:Alprazolam